You are here: Welcome » Kyla Hildebrand

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
kyla_hildebrand [2022/04/18 09:32]
liam [Education]
kyla_hildebrand [2022/04/18 22:26] (current)
liam [Funding]
Line 7: Line 7:
 ===== Education ===== ===== Education =====
  
-Hildebrand completed medical school at the [[University of Manitoba]], Pediatrics Residency at the [[University of Alberta]], and a fellowship in Clinical Immunology and Allergy at the [[University of Toronto]]. She completed a Master of Science in Community Health at the University of Toronto and was the 2010 recipient of the [[Royal College of Physicians and Surgeons of Canada]] Fellowship for Studies in Medical Education.+Hildebrand completed medical school at the [[University of Manitoba]] in 2005, Pediatrics Residency at the [[University of Alberta]], and a fellowship in Clinical Immunology and Allergy at the [[University of Toronto]].((//Hildebrand, Kyla Jade - Doctor Details.// (2013, June 3). College of Physicians and Surgeons of Ontario. https://archive.ph/b2elA)) ((//Kyla Hildebrand - Clinical Assistant Professor of Pediatrics Allergy and Immunology in Vancouver, British Columbia, Canada.// eMedEvents. Retrieved April 18, 2022, from https://web.archive.org/web/20220418074053/https://www.emedevents.com/speaker-profile/kyla-hildebrand)) She completed a Master of Science in Community Health at the University of Toronto and was the 2010 recipient of the [[Royal College of Physicians and Surgeons of Canada]] Fellowship for Studies in Medical Education. 
 ===== Affiliations ===== ===== Affiliations =====
 +
 +Hildebrand began her academic career at the [[University of Western Ontario]].
  
 Hildebrand is a researcher at the [[BC Children's Hospital Research Institute]].((//Kyla Hildebrand.// BC Children’s Hospital Research Institute. Retrieved April 17, 2022, from https://www.bcchr.ca/khildebrand)) She is also a clinical associate professor in the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, at the [[University of British Columbia]].((//Welcome to Dr. Kyla Hildebrand | Department of Pediatrics.// (2013, September 3). University of British Columbia. https://archive.ph/BMCDk)) Hildebrand is a researcher at the [[BC Children's Hospital Research Institute]].((//Kyla Hildebrand.// BC Children’s Hospital Research Institute. Retrieved April 17, 2022, from https://www.bcchr.ca/khildebrand)) She is also a clinical associate professor in the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, at the [[University of British Columbia]].((//Welcome to Dr. Kyla Hildebrand | Department of Pediatrics.// (2013, September 3). University of British Columbia. https://archive.ph/BMCDk))
 +
 +Hildebrand sits on the board of directors for the [[Canadian Society of Allergy and Clinical Immunology]] (CSACI), and has received honoraria from the [[BC Society of Allergy and Immunology]] (BCSAI).((Li, L. D. X., Abrams, E. M., Lavine, E., Hildebrand, K., & Mack, D. P. (2021). //CSACI position statement: transition recommendations on existing epinephrine autoinjectors.// Allergy, Asthma & Clinical Immunology, 17(1). https://doi.org/10.1186/s13223-021-00634-2)) ((//Program Directors.// Canadian Society of Allergy and Clinical Immunology. Retrieved April 18, 2022, from https://archive.ph/EAVaX))
 +
 +===== Research =====
 +
 +==== Funding ====
 +
 +Hildebrand has received funding from [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:CSL Behring]], [[pharmaceutical_companies:MEDA Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Shire Pharma]], [[pharmaceutical_companies:Stallergenes Greer]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[pharmaceutical_companies:Aralez]] and
 +[[pharmaceutical_companies:Pediapharm]] as recently as 2018.((Quirt, J., Hildebrand, K. J., Mazza, J., Noya, F., & Kim, H. (2018). //Asthma.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0279-0)) ((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) She has also received speakers fees from [[pharmaceutical_companies:Novartis]], and paid travel expenses for [[AllerGen]].((Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). //First real-world safety analysis of preschool peanut oral immunotherapy.// The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010))
 +
 +She has also served as a consultant for [[Food Allergy Canada]], and has received honoraria from [[Health Canada]]. She received a research grant from the [[Canadian Allergy, Asthma, and Immunology Foundation]].((Waserman, S., Cruickshank, H., Hildebrand, K. J., Mack, D., Bantock, L., Bingemann, T., Chu, D. K., Cuello-Garcia, C., Ebisawa, M., Fahmy, D., Fleischer, D. M., Galloway, L., Gartrell, G., Greenhawt, M., Hamilton, N., Hourihane, J., Langlois, M., Loh, R., Muraro, A., & Rosenfield, L. (2021). //Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines.// Journal of Allergy and Clinical Immunology, 147(5), 1561–1578. https://doi.org/10.1016/j.jaci.2021.01.034))
 +
 +[[Food Allergy Canada]] is partnered with [[pharmaceutical_companies:Pfizer]].((//Who we work with.// Food Allergy Canada. Retrieved April 18, 2022, from https://archive.ph/e2uhY))
 +
 +She has received further funding from [[Genome British Columbia]] and the [[BC Children's Hospital Foundation]].((Blanchard-Rohner, G., Ragotte, R. J., Junker, A. K., Sharma, M., Del Bel, K. L., Lu, H. Y., Erdle, S., Chomyn, A., Gill, H., Tucker, L. B., Schreiber, R. A., Rozmus, J., Biggs, C. M., Hildebrand, K. J., Wu, J., Stockler-Ipsiroglu, S., & Turvey, S. E. (2021). //Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report.// BMC Pediatrics, 21(1). https://doi.org/10.1186/s12887-021-02508-3)) ((Roberts, H., Soller, L., Ng, K., Chan, E. S., Roberts, A., Kang, K., Hildebrand, K. J., & Wong, T. (2020). //First pediatric electronic algorithm to stratify risk of penicillin allergy.// Allergy, Asthma & Clinical Immunology, 16(1). https://doi.org/10.1186/s13223-020-00501-6)) She has published NACI papers with funding from the [[Public Health Agency of Canada]].((Dayneka, N., Jensen, C., & Hildebrand, K. (2020). //Canadian Immunization Guide: “Anaphylaxis and other acute reactions following vaccination” chapter update.// Canada Communicable Disease Report, 46(1112), 384–386. https://doi.org/10.14745/ccdr.v46i1112a04))
Back to top